Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc stock logo
CRMD
CorMedix
$14.34
+1.4%
$12.28
$5.31
$17.43
$1.07B1.711.97 million shs3.87 million shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$10.07
+0.6%
$5.75
$3.35
$20.30
$283.73M1.04144,775 shs178,503 shs
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$19.14
+0.7%
$19.11
$13.22
$45.37
$1.10B-1.89860,675 shs297,993 shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$19.74
+2.3%
$13.77
$5.35
$19.97
$1.08B1.15805,681 shs406,106 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc stock logo
CRMD
CorMedix
+1.07%+4.59%+18.03%+15.71%+129.17%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
+2.14%+12.85%+81.67%+180.39%-49.62%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
+0.96%+2.32%+4.00%-15.25%-53.74%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-0.36%-0.10%+50.66%+98.36%+39.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CorMedix Inc stock logo
CRMD
CorMedix
2.7079 of 5 stars
3.41.00.00.03.80.01.9
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3.1744 of 5 stars
3.65.00.00.02.70.80.6
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.8687 of 5 stars
3.53.00.00.02.91.70.6
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
4.4765 of 5 stars
4.61.00.04.82.10.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CorMedix Inc stock logo
CRMD
CorMedix
2.86
Moderate Buy$17.3320.87% Upside
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3.17
Buy$22.75125.92% Upside
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
3.00
Buy$75.71295.58% Upside
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3.22
Buy$25.5729.57% Upside

Current Analyst Ratings Breakdown

Latest CTNM, GPCR, STOK, and CRMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$28.00
8/18/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $21.00
8/13/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00
8/13/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.00
8/8/2025
CorMedix Inc stock logo
CRMD
CorMedix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $17.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$75.00 ➝ $60.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$92.00 ➝ $90.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$89.00 ➝ $87.00
7/18/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
7/1/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/30/2025
CorMedix Inc stock logo
CRMD
CorMedix
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CorMedix Inc stock logo
CRMD
CorMedix
$43.47M24.63N/AN/A$2.96 per share4.84
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/A$6.11 per shareN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$13.40 per shareN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$199.89M5.41N/AN/A$6.11 per share3.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CorMedix Inc stock logo
CRMD
CorMedix
-$17.93M$0.7519.1215.26N/A42.11%42.73%34.19%10/29/2025 (Estimated)
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$42.26M-$2.20N/AN/AN/AN/A-29.75%-28.08%11/5/2025 (Estimated)
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$122.53M-$1.05N/AN/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$88.98M$0.8523.22N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)

Latest CTNM, GPCR, STOK, and CRMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million
8/7/2025Q2 2025
CorMedix Inc stock logo
CRMD
CorMedix
$0.20$0.28+$0.08$0.28$29.88 million$39.74 million
8/6/2025Q2 2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.28-$0.36-$0.08-$0.36N/AN/A
8/5/2025Q2 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CorMedix Inc stock logo
CRMD
CorMedix
N/A
7.82
7.52
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
24.51
24.51
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
20.48
20.48
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
6.98
6.98

Institutional Ownership

CompanyInstitutional Ownership
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
CorMedix Inc stock logo
CRMD
CorMedix
5.30%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
11.30%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
5.60%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
9.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
CorMedix Inc stock logo
CRMD
CorMedix
3074.65 million70.69 millionOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3128.04 million24.87 millionN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13657.60 million54.37 millionOptionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10054.80 million49.59 millionOptionable

Recent News About These Companies

Stoke Therapeutics: Vulnerable To Profit Taking
Stoke Therapeutics Beats Shareholder Challenge to Board Bylaw
FY2025 Earnings Estimate for STOK Issued By Chardan Capital
Leerink Partnrs Has Optimistic Outlook of STOK Q3 Earnings
HC Wainwright Issues Optimistic Forecast for STOK Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

CorMedix stock logo

CorMedix NASDAQ:CRMD

$14.34 +0.20 (+1.41%)
Closing price 03:59 PM Eastern
Extended Trading
$14.35 +0.01 (+0.07%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$10.07 +0.06 (+0.60%)
Closing price 03:59 PM Eastern
Extended Trading
$10.06 -0.01 (-0.05%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$19.14 +0.14 (+0.74%)
Closing price 03:59 PM Eastern
Extended Trading
$19.12 -0.02 (-0.10%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$19.74 +0.44 (+2.25%)
Closing price 03:59 PM Eastern
Extended Trading
$19.79 +0.05 (+0.28%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.